VERV's logo.
Ticker Symbol: VERV

Verve Therapeutics Inc

$44.97 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001840574

Company Profile

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $12.29
Change: $0.51 ( 4.33%)
Days Range: $11.39 - $12.30
Beta: 2.16
52wk. High: $40.88
52wk. Low: $9.63
Ytd. Change -34.79%
50 Day Moving Average: $12.34
200 Day Moving Average: $15.92
Shares Outstanding: 63721263

Valuation

Market Cap: 78.3B
PE Ratio: -3.88
EPS (TTM): -3.17

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A